Route comparison — subcutaneous vs intramuscular vs intravenous for peptides

This is a decision that belongs in a clinical conversation, not in a YouTube comment section.

Subcutaneous injection is the most common route for wellness and research peptides in self-administration contexts, and the reasons are practical as well as pharmacological. The subcutaneous space — the adipose tissue layer just beneath the skin — is highly vascularized but not as acutely so as muscle, which means absorption from subcutaneous sites is gradual and sustained over hours rather than peaking sharply and declining quickly. For peptides like sermorelin, ipamorelin, and BPC-157, where the goal is a sustained physiological effect rather than an acute peak, the slower absorption profile of subcutaneous delivery is actually appropriate. The technique is accessible: insulin syringes, short needles, a pinch of belly fat, a 45-degree angle. Site rotation matters — injecting the same area repeatedly causes local lipodystrophy and unpredictable absorption. The abdomen, lateral thighs, and upper outer arms are typical sites, rotated systematically.

The pharmacological reality of subcutaneous absorption is that the subcutaneous space acts as a slow-release depot. Peptide concentrations in plasma rise more slowly, peak at a lower concentration, and remain measurable for a longer period than the same dose injected intramuscularly. For GH secretagogues, this matters: the pulsatile nature of GH secretion is the target, and a sustained modest stimulus from subcutaneous delivery may be more physiologically appropriate than a sharp spike that the feedback system quickly dampens.

Intramuscular injection delivers the compound into well-vascularized muscle tissue, producing faster absorption and a more pronounced initial plasma peak. The classic IM compounds in this context include HCG, which has traditionally been given intramuscularly in fertility and testosterone-adjacent protocols, and some of the injectable compounds used in the Russian tradition of neurological and recovery medicine — Cortexin, for instance, is typically given IM. Larger volumes are feasible via the intramuscular route than subcutaneously: while subcutaneous injections are generally kept below 1 to 1.5 mL per site to avoid discomfort and absorption issues, intramuscular injections into the ventrogluteal or vastus lateralis can accommodate 3 to 5 mL if the dose requires it. IM injections use longer needles — typically 1 to 1.5 inches — and land in muscle rather than the fat layer above it.

The clinical trend over the past decade has moved many compounds from IM to subcutaneous as evidence has accumulated showing comparable or equivalent outcomes with improved tolerability. HCG, the clearest example: traditionally IM, it's now prescribed subcutaneously in most testosterone replacement adjacent protocols because subcutaneous HCG produces comparable LH-equivalent effect with less injection discomfort and easier patient self-administration. The same logic applies wherever the pharmacokinetic difference between IM and subQ doesn't materially change the clinical outcome — the route that's more tolerable and easier to administer consistently is usually preferable for long-term compliance.

Intravenous administration puts the compound directly into venous blood, bypassing absorption entirely. Bioavailability is by definition 100% for IV-administered compounds — there is no absorption step, no lag time, no depot effect. Peak plasma concentration is achieved immediately or within the infusion window. This makes IV the route of choice when rapid, complete delivery is required: in acute clinical settings, for compounds with very poor absorption by other routes, or for compounds where the therapeutic window requires precise plasma level management.

NAD+ infusion is the most common IV peptide-adjacent protocol in wellness contexts. NAD+ given intravenously achieves plasma concentrations that oral supplementation can't approach, and the clinical use of IV NAD+ in addiction medicine and neurological recovery contexts has generated genuine clinical interest. The time commitment is significant — IV NAD+ infusions often run two to four hours per session — and the cost reflects both the compound and the clinical infrastructure required. That infrastructure is the point: IV administration requires venous access, appropriate clinical supervision, and sterile technique that is categorically different from subcutaneous self-injection. The infection risk calculus for IV administration is genuinely different from subcutaneous or IM, because an error in sterility has direct access to the bloodstream rather than being filtered through the absorption process.

Glutathione IV infusions follow the same logic — IV delivery achieves plasma concentrations that oral glutathione largely cannot, because oral glutathione is cleaved into its constituent amino acids in the gut before reaching systemic circulation. Whether IV-achieved plasma glutathione levels translate into the intracellular glutathione concentrations where the antioxidant effects actually matter is a pharmacological question with a more complicated answer than IV glutathione marketing typically suggests, but the route rationale is sound: if systemic glutathione delivery is the goal, IV achieves it when oral cannot.

Subcutaneous glutathione is used in some compounding protocols as a middle path — better than oral, more accessible than IV, though the pharmacokinetics differ from IV in the ways described above. Subcutaneous glutathione absorption and the stability of the compound in subcutaneous tissue are not as thoroughly characterized as IV pharmacokinetics, which is the honest caveat for this route.

Thymosin Alpha-1 is typically subcutaneous — the clinical trials that established its effects used subcutaneous injection twice weekly, and the compound's pharmacology doesn't require the rapid systemic distribution that IV provides. Subcutaneous administration of TA-1 produces plasma peaks over several hours and a sustained immunomodulatory effect consistent with the twice-weekly dosing schedule used in the research. BPC-157 for systemic effects is typically subcutaneous or intramuscular; for gastric or gut applications, oral administration has preclinical support. Sermorelin, ipamorelin, and other GH secretagogues are subcutaneous by convention and pharmacological appropriateness. These aren't arbitrary recommendations — they reflect the routes used in the studies that generated the evidence for these compounds, and deviating from those routes means you're extrapolating beyond what the existing data supports.

The infection risk hierarchy is worth stating plainly. Subcutaneous injection, done correctly with sterile technique, single-use needles, and appropriate skin preparation, carries a low infection risk. Intramuscular injection done with the same sterile care carries a comparable but slightly higher risk due to the depth of tissue involved and the consequences of introducing bacteria into muscle versus subcutaneous fat. Intravenous access carries the highest infection risk of the three and requires clinical-grade sterile technique — this is not a route appropriate for home self-administration, and it isn't presented as one in responsible clinical practice. Any IV administration should happen under clinical supervision with sterile technique, appropriate venous access assessment, and monitoring.

Patient comfort matters for compliance in a way that clinicians sometimes underweight. A compound that requires twice-weekly IM injections that are consistently painful and that you eventually skip has worse real-world efficacy than a subcutaneous alternative that you actually do. This is not an argument for choosing routes based on comfort over pharmacology — the pharmacology determines what route achieves the therapeutic goal. But when two routes have comparable pharmacological profiles for a specific compound and specific application, the one that's more comfortable and more likely to be administered correctly and consistently is the better choice. That tradeoff should be explicit in the clinical conversation.

The decision framework reduces to these questions: what does the pharmacology of this specific compound require in terms of absorption rate, peak concentration, and duration? What route was used in the evidence base — studies, trials, observational data — that supports this compound's use? Does the proposed route match the infrastructure available to the patient — clinical supervision for IV, appropriate technique for IM, self-administration competence for subcutaneous? What is the tolerance profile of the patient for the discomfort and technique demands of each route?

These are clinical questions. They have clinical answers. The right source for those answers is your prescribing provider with knowledge of the compound's pharmacology and your specific situation — not a protocol built from forum posts by people who may have different compounds, different doses, different goals, and different baselines than you do. Route decisions look like details. In pharmacology, details are where outcomes are made and where errors happen. Treat them accordingly.